Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications

Por Pisano, M., Baldinu, P., Sini, M. C., Ascierto, P. A., Tanda, F., Palmieri, G.
Publicado em 2008

Report from the Melanoma Independent Board First Melanoma MIB Conference, 21–22 October 2013

Por Testori, A, Ascierto, P, Chiarion Sileni, V, De Lorenzo, F, Pelicci, PG, Rossi, CR
Publicado em 2014

Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases

Por Palmieri, G, Cossu, A, Ascierto, P A, Botti, G, Strazzullo, M, Lissia, A, Colombino, M, Casula, M, Floris, C, Tanda, F, Pirastu, M, Castello, G
Publicado em 2000

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

Por Galon, J., Fox, B. A., Bifulco, C. B., Masucci, G., Rau, T., Botti, G., Marincola, F. M., Ciliberto, G., Pages, F., Ascierto, P. A., Capone, M.
Publicado no J Transl Med (2016)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma

Por De Divitiis, C., von Arx, C., Grimaldi, A. M., Cicala, D., Tatangelo, F., Arcella, A., Romano, G. M., Simeone, E., Iaffaioli, R. V., Ascierto, P. A., Tafuto, S.
Publicado no J Transl Med (2016)

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Por Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., Savage, K. J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H. B., Waxman, I. M., Abernethy, A. P.
Publicado no Ann Oncol (2016)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

Por Chiarion-Sileni, V, Pigozzo, J, Ascierto, P A, Simeone, E, Maio, M, Calabrò, L, Marchetti, P, De Galitiis, F, Testori, A, Ferrucci, P F, Queirolo, P, Spagnolo, F, Quaglino, P, Carnevale Schianca, F, Mandalà, M, Di Guardo, L, Del Vecchio, M
Publicado em 2014

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

Por Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J.-J., Murawa, P., Dreno, B., Ross, M., Weber, J., Hauschild, A., Rutkowski, P., Testori, A., Levchenko, E., Enk, A., Misery, L., Vanden Abeele, C., Vojtek, I., Peeters, O., Brichard, V. G., Therasse, P.
Publicado no Ann Oncol (2016)

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

Por Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F
Publicado no ESMO Open (2016)